Preharvest donor hyperoxia predicts good early graft function and longer graft survival after liver transplantation

Liver Transplantation

Volumn 11, Issue 2, 2005, Pages 140-151

  Corradini, Stefano Ginanni ^a,b   Elisei, Walter ^a   De Marco, Rosanna ^a   Siciliano, Maria ^a   Iappelli, Massimo ^a   Pugliese, Francesco ^a   Ruberto, Franco ^a   Nudo, Francesco ^a   Pretagostini, Renzo ^a   Bussotti, Alessandro ^a   Mennini, Gianluca ^a   Eramo, Annarita ^a   Liguori, Francesca ^a   Merli, Manuela ^a   Attili, Adolfo Francesco ^a   Muda, Andrea Onetti ^a   Natalizi, Stefania ^a   Berloco, Pasquale ^a   Rossi, Massimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b University La Sapienza ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYCLOSPORIN; DOBUTAMINE; DOPAMINE; GLUCOSE; HEMOGLOBIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NORADRENALIN; POTASSIUM; PROTHROMBIN; SODIUM; VASOACTIVE AGENT;

ABDOMINAL BLEEDING; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTERIAL OXYGEN TENSION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DONOR; FATALITY; FEMALE; GLUCOSE BLOOD LEVEL; GRAFT FAILURE; GRAFT SURVIVAL; HEART ARREST; HEMOGLOBIN DETERMINATION; HUMAN; HYPEROXIA; HYPOTENSION; INTRAOPERATIVE PERIOD; LEUKOCYTE COUNT; LIVER DISEASE; LIVER TRANSPLANTATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; MULTIVARIATE ANALYSIS; OXYGEN SATURATION; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; POTASSIUM BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; RECIPIENT; SCHOOL CHILD; SCORING SYSTEM; SEPSIS; SODIUM BLOOD LEVEL; SURGICAL TECHNIQUE; THROMBOCYTE COUNT; VEIN BYPASS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; BLOOD GAS ANALYSIS; CHILD; FEMALE; GRAFT SURVIVAL; HUMANS; LIVER TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS; OXYGEN; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TISSUE AND ORGAN HARVESTING;

EID: 20944442104     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20339     Document Type: Article

References (45)

1. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl 2003;9:651-663.
2. Yanaga K, Tzakis AG, Starzl TE. Personal experience with the procurement of 132 liver allografts. Transpl Int 1989;2:137-142.
3. Mor E, Klintmalm GB, Gonwa TA, Solomon H, Holman MJ, Gibbs JF, et al. The use of marginal donors for liver transplantation. Transplantation 1992;53:383-386.
4. Ploeg RJ, D'Alessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffmann RM, et al. Risk factors for primary dysfunction after liver transplantation - a multivariate analysis. Transplantation 1993;55:807-813.
5. Gonzàlez FX, Rimola A, Grande L, Antolin M, Garcia-Valdecasas JC, Fuster J, et al. Predictive factors of early postoperative graft function in human liver transplantation. Hepatology 1994; 20:565-573.
6. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994;20:829-838.
7. De Carlis L, Sansalone CV, Rondinara GF, Colella G, Slim AO, Rossi O, et al. Is the use of marginal donors justified in liver transplantation? Analysis of results and proposal of modern criteria. Transpl Int 1996;9:S414-S417.
8. Chui AK, Shi LW, Rao ARN, Verran DJ, Painter D, Koorey D, et al. Donor fatty (steatotic) liver allografts in orthotopic liver transplantation: a revisit. Transplant Proc 2000;32:2101-2102.
9. Nanashima A, Pillay P, Verran DJ, Painter D, Nakasuji M, Crawford M, et al. Analysis of initial poor graft function after orthotopic liver transplantation: experience of an Australian single liver transplantation center. Transplant Proc 2002;34: 1231-1235.
10. Rull R, Vidal O, Momblan D, Gonzalez FX, Lopez-Boado MA, Fuster J, et al. Evaluation of potential liver donors: limits imposed by donor variables in liver transplantation. Liver Transpl 2003;9:389-393.
11. Verran D, Kusyk T, Painter D, Fisher J, Korrey D, Strasser S, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 2003;9:500-505.
12. Salizzoni M, Franchello A, Zamboni F, Ricchiuti A, Cocchis D, Fop F, et al. Marginal grafts: finding the correct treatment for fatty livers. Transpl Int 2003;16:486-493.
13. McKinley BA, Parmley CL. Clinical trial of an ex vivo arterial blood gas monitor. J Crit Care 1998;13:190-197.
14. Figueras J, Busquets J, Grande L, Jaurrieta E, Perez-Ferreiroa J, Mir J, et al. The deleterious effect of donor high plasma sodium and extended preservation in liver transplantation. Transplantation 1996;61:410-413.
15. Totsuka E, Fung JJ, Urakami A, Moras N, Ishii T, Takahashi K, et al. Influence of donor cardiopulmonary arrest In human liver transplantation: possible role of ischemic preconditioning. Hepatology 2000;31:577-580.
16. Maring JK, Klompmaker IJ, Zwaveling JH, Kranenburg K, Ten Vergert EM, Slooff MJ. Poor initial graft function after orthotopic liver transplantation: can it be predicted and does it affect outcome? An analysis of 125 adult primary transplantations. Clin Transplant 1997;11:373-379.
17. Ardite E, Ramos C, Rimola A, Grande L, Fernández-Checa JC. Hepatocellular oxidative stress and initial graft injury in human liver transplantation. J Hepatol 1999;31:921-927.
18. Fernandez-Merino FJ, Nuño-Garza J, Lopez-Hervas P, Sanjuan-benito A, López-Buenadicha A, Quijano-Collazo Y, et al. Survival and complication rates in liver transplant patients showing primary dysfunction versus normofunction. Transplant Proc 2003;35:1815-1817.
19. Heise M, Settmacher U, Pfitzmann R, Wünscher U, Müller AR, Jonas S, Neuhaus P. A survival-based scoring-system for initial graft function following orthotopic liver transplantation. Transpl Int 2003;16:794-800.
20. Garcia-Valdecasas JC, Gonzalez FJ, Grande L, Rimola A, Navasa M, Fuster J, et al. The use of the University of Wisconsin and Euro-Collins solutions either alone or in a combined method. Transpl Int 1992;5:77-80.
21. Grande L, Rimola A, Garcia-Valdecasas JC, Mas A, Fuster J, Navasa M, et al. Recovery of liver graft after initial poor function. Transplantation 1992;53:228-230.
22. Verran DJ, Gurkan A, Dilworth P, Painter D, Chui A, Dorney S, et al. Inferior liver allograft survival from cadaveric donors > 50 years of age? Clinical Transplant 2001;15:106-110.
23. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.
24. Chui AK, Haghighi K, Painter D, Jayasundera M, Hall G, Rao ARN,, et al. Donor fatty (steatotic) liver allograft in orthotopic liver transplantation. Transplant Proc 1998;30:3286-3287.
25. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology: a basic science for clinical medicine. Little Brown and Co., Boston/Toronto, 2nd ed., 1991:24-34.
26. Osborn DA, Lockley C, Jeffery HE, Lloyd J, Lazarus R. Inter-observer reliability of the click test: a rapid bedside test to determine surfactant function. J Paediatr Child Health 1998;34:544-547.
27. Briceno J, Solorzano G, Pera C. A proposal for scoring marginal liver grafts. Transpl Int 2000;13:S249-S252.
28. Todo S, Demetris AJ, Makowka L, Teperman L, Podesta L, Shaver T, et al. Primary nonfunction of hepatic allografts with preexisting fatty infiltration. Transplantation 1989;47:903-905.
29. D'Alessandro AM, Kalayoglu M, Sollinger HW, Hoffmann RM, Reed A, Knechtle SJ, et al. The predictive value of donor liver biopsies on the development of primary nonfunction after orthotopic liver transplantation. Transplant Proc 1991;23:1536-1537.
30. Adam R, Reynes M, Johann M, Morino M, Astarcioglu I, Kafetzis I, et al. The outcome of steatotic grafts in liver transplantation. Transplant Proc 1991;23:1538-1540.
31. Yoo HY, Molmenti E, Thuluvath PJ. The effect of donor body mass index on primary graft nonfunction, retransplantation rate, and early graft and patient survival after liver transplantation. Liver Transpl 2003;9:72-78.
32. Tähepôld P, Valen G, Starkopf J, Karaine C, Zilmer M, Vaage J. Pretreating rats with hyperoxia attenuates ischemia-reperfusion injury of the heart. Life Sci 2001;68:1629-1640.
33. Tähepôld P, Ruusalepp A, Li G, Vaage J, Starkopf J, Valen G. Cardioprotection by breathing hyperoxic gas-relation to oxygen concentration and exposure time in rats and mice. Eur J Cardiothorac Surg 2002;21:987-994.
34. Tähepôld P, Vaage J, Starkopf J, Valen G. Hyperoxia elicits myocardial protection through a nuclear factor κB-dependent mechanism in the rat heart. J Thorac Cardiovasc Surg 2003;125: 650-660.
35. Minor T, Klauke H, Nagelschmidt M, Isselhard W. Reduction of proteolysis by venous-systemic oxygen persufflation during rat liver preservation and improved functional outcome after transplantation. Transplantation 1997;63:365-368.
36. Kamiike W, Burdelski M, Steinhoff G, Ringe B, Lauchart W, Pichlmayr R. Adenine nucleotide metabolism and its relation to organ viability in human liver transplantation. Transplantation 1988;45:138-143.
37. Lanir A, Jenkins RL, Caldwell C, Lee RGL, Khettry U, Clouse ME. Hepatic transplantation survival: correlation with adenine nucleotide level in donor liver. Hepatology 1988;8:471-475.
38. Yanagi K, Oshima N. Improvement of metabolic performance of cultured hepatocytes by high oxygen tension in the atmosphere. Artif Organs 2001;25:1-6.
39. Calmus Y, Cynober L, Dousset B, Lim SK, Soubrane O, Conti F, et al. Evidence for the detrimental role of proteolysis during liver preservation in humans. Gastroenterology 1995;108:1510-1516.
40. Sindram D, Rüdiger HA, Upadhya AG, Strasberg SM, Clavien PA. Ischemic preconditioning protects against cold ischemic injury through an oxidative stress dependent mechanism. J Hepatol 2002;36:78-84.
41. Broughan TA, Douzdjian V. Donor liver selection. The South-Eastern Organ Procurement Foundation Liver Committee. Am Surg 1998;64:785-790.
42. Wang P, Tait SM, Chaudry IH. Sustained elevation of norepinephrine depresses hepatocellular function. Biochim Biophys Acta 2000;1535:36-44.
43. Iwai M, Shimazu T. Exaggeration of acute liver damage by hepatic sympathetic nerves and circulating catecholamines in perfused liver of rats treated with d-galactosamine. Hepatology 1996;23:524-529.
44. Yang S, Koo DJ, Zhou M, Chaudry IH, Wang P. Gut-derived norepinephrine plays a critical role in producing hepatocellular dysfunction during early sepsis. Am J Physiol Gastrointest Liver Physiol 2000;279:G1274-G1281.
45. Zhou M, Yang S, Koo DJ, Ornan DA, Chaudry IH, Wang P. The role of Kupffer cell alpha(2)-adrenoceptors in norepinephrine induced TNF-alpha production. Biochim Biophys Acta 2001;1537:49-57.